SuspendedPhase 2NCT05832255

An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nova Mentis Life Science Corp
Principal Investigator
David Crowley, MD
KGK Science Inc.
Intervention
Psilocybin, 1.5 mg(drug)
Enrollment
10 enrolled
Eligibility
18-50 years · All sexes
Timeline
20232024

Study locations (1)

Collaborators

KGK Science Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05832255 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome

← Back to all trials